Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-29 | Dr. Schwartz has wide-ranging experience as a drug development expert in pharmaceutical and biotechnology industries primarily in oncology, hematology, and rare diseases. He received his medical degree from the University of Pretoria, South Africa. |
| 2022-04-26 | He received his medical degree from the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada and practiced medicine prior to his career in the biopharmaceutical industry. |
| 2023-11-14 | Dr. Brian Schwartz(5) Includes options to purchase 132 shares of Common Stock that are exercisable within 60 days of November 6, 2023. |
| 2024-05-08 | Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada and practiced medicine prior to his career in the biopharmaceutical industry. |
Data sourced from SEC filings. Last updated: 2026-02-03